ENO2 has been upregulated in various tumor types, including head and neck cancer [39], colorectal cancer [41], pancreatic cancer [42], and bladder cancer [43], and has been associated with more aggressive phenotypes. This evidence concerns the gene ENO2 and urinary bladder cancer.